|I. COMMENCED TRADING IN AUGUST|
|Company (Symbol)#||Date Filed||Date Comm.||Shares/Units (M)||Price||Shares Out (M)@||Lead, Other Underwriters||Gross (US$M)||Post-Offering Market Cap (M)%|
|Sucampo Pharmaceuticals Inc. (SCMP)1||6/19/06||8/3/07||3.125S||$11.50||41.7||Cowen & Co. CIBC World Markets Leerink Swann & Co.||$35.94||$479.55|
Number of IPOs in August: 1
Average value of August IPOs: $35.94Number of IPOs in 2007: 31
Total raised in IPOs in 2007: $1,563.20MAverage value of IPOs in 2007: $50.43M
|Company (Symbol)#||Date Filed||Date Comm.||Shares/ Units (M)||Price||Shares Out (M)@||Lead, Other Underwriters||Gross (M)||Post-Offering Market Cap (M)%|
|NeoStem Inc.(AMEX:NBS)2||8/14||8/14||1.27U||$4.96||4||Mercer Capital Ltd.||$6.3||$19.84|
Number of follow-on offerings in August: 1Average value of August follow-ons: $6.3M
Number of follow-on offerings in 2007: 39Total raised in follow-ons in 2007: $2,480.70M
Average value of follow-ons in 2007: $63.61M
|# Unless otherwise indicated, shares are traded on the Nasdaq exchange.@ This column reflects the shares outstanding following the offering, when disclosed. % Market capitalization is calculated based on the offering price. Currency conversions are based on exchange rates at the time of the deal. AMEX = American Stock Exchange.|
1 Sucampo's IPO was worth $43.1M, with a stockholder offering 625,000 shares in addition to the 3.125M offered by the company. Underwriters exercised in full their option for 562,500-shares, which were sold by the stockholder.
2 NeoStem sold 1.27M units, each consisting of one share of common stock and half of a five-year warrant to purchase another share at $6.
|II. FILED AND PENDING|
|Company (Symbol/Proposed Symbol)#*||Date Filed||Shares/ Units (M)||Price Range||Shares Out (M)@||Lead, Other Underwriters||Value (M)|
|Adnexus Therapeutics Inc. (ADNX)||8/22/07||N/A||N/A||N/A||Lehman Brothers UBS Securities (co-lead),Cowen & Co. Lazard Freres & Co. LLC||$86|
|Anacor Pharmaceuticals Inc. (ANAC)||8/31/07||N/A||N/A||N/A||Morgan Stanley & Co. Inc. Cowen & Co. LLC (co-lead) Pacific Growth Equities LLC Needham & Co. LLC||$57.5|
|Archemix Corp. (ARCH)||7/25/07||N/A||N/A||N/A||Banc of America Securities Bear, Stearns & Co. Inc.Cowen and Co.||$69|
|ARYx Therapeutics Inc. (ARYX)||8/31/07||N/A||N/A||N/A||Morgan Stanley & Co. Inc. CIBC World Markets Corp. Jefferies & Co. Inc. Leerink Swann & Co. Inc.||$86.25|
|Bioheart Inc. (BHRT)||2/13/07||N/A||N/A||21.5||BMO Capital Markets Corp. Janney Montgomery Scott (co-lead) Merriman Curhan Ford & Co.||$35|
|Biolex Inc. (BLEX)||8/14/07||N/A||N/A||N/A||Lehman Brothers Inc. Deutsche Bank Securities (co-lead) Leerink Swann & Co. Inc.||$70|
|Genoptix Inc. (GXDX)||8/1/07||N/A||N/A||N/A||Lehman Brothers Banc of America Sec. Cowen and Co.||$86.25|
|Insys Therapeutics Inc. (INRX)||8/20/07||N/A||N/A||N/A||Banc of America Securities UBS Investment Bank (co-lead) JMP Securities Natixis Bleichroeder||$86.25|
|Light Sciences Oncology Inc. (LSON)||4/21/06||5.25S||$14-$16||18.5||Cowen & Co. Wachovia Securities (co-lead) Jefferies & Co. Thomas Weisel Partners||$78.75|
|MAP Pharmaceuticals Inc. (MAPP)||6/18/07||N/A||N/A||N/A||Merrill Lynch & Co. Morgan Stanley (co-lead) Deutsche Bank Sec.||$86.25|
|Merrion Pharmaceuticals Ltd. (MERR)1||4/3/07||N/A||N/A||N/A||Punk, Ziegel & Co. Goodbody Stockbrokers Stanford Group Co.||$46|
|MonoSol Rx Inc.|
|5/14/07||4S||$16-$18||N/A||Cowen and Co. CIBC World Markets Susquehanna Financial||$68|
|Nanoshere Inc. (NSPH)||8/13/07||N/A||N/A||N/A||Credit Suisse Piper Jaffray Leerink Swann & Co. Allen & Co. LLC||$100|
|2/15/07||5S||$4-$6||21.1||Dundee Securities Desjardins Sec. International Blackmont Capital||$25|
|8/10/07||N/A||N/A||N/A||Merrill Lynch & Co.|
Cowen & Co. LLCThomas Weisel Partners
Leerink Swann & Co.Merrill Lynch International Wilson HTM
|Precision Therapeutics Inc.||8/24/07||N/A||N/A||N/A||JP Morgan Piper Jaffray (co-lead) JMP Securities||$80.5|
|Reliant Pharmaceuticals Inc. (NYSE:RRX)||8/10/07||N/A||N/A||N/A||Goldman, Sachs & Co. Merrill Lynch & Co. (co-lead) Bank of America Securities Lazard Capital Markets||$400|
|Talecris Biotherapeutics Holdings Corp. (TLCR)||7/30/07||N/A||N/A||N/A||Morgan Stanley Goldman Sachs & Co. J.P. Morgan||$1B|
|5/14/07||N/A||N/A||N/A|| Credit Suisse Securities|
Cowen and Co.Lazard Capital Markets Leerink Swann and Co.
Inc. (Canada; CDNX:BIP)4
Laurentian Bank Sec.
|Chemokine Therapeutics Corp. (Canada; TSX:CTI; OTC BB: CHKT)||5/30/07||N/A||N/A||N/A||GMP Securities||$25|
|Neurobiological Technologies Inc. (NTII)||8/13/07||N/A||N/A||N/A||Merriman Curhan Ford||$75|
|Neurochem Inc. (NRMX)||1/18/07||N/A||N/A||N/A||N/A||$102|
|# Unless otherwise indicated, shares are traded on the Nasdaq exchange; general shelf registration statements are not included until action is taken on the filing.|
* Stock symbols for companies seeking to complete IPOs are proposed.@ This column reflects the shares outstanding following the offering, when disclosed.
The value of all offerings is based on either the midpoint of the price range listed in the company's SEC filing or the most recent closing stock price before the offering was announced. In some cases, the company has not disclosed the number of shares to be offered or a price range. Then, the value is the maximum aggregate offering price listed in the SEC filing.\N/A = Not available, applicable or reported.
AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange.1 Merrion plans to list American depositary shares on Nasdaq and ordinary shares in a secondary listing on the Irish Enterprise Exchange, both under the ticker "MERR."
2 NovaBay is seeking a dual listing on the American and Toronto stock exchanges.3 Peplin Ltd., of Australia, established the U.S. subsidiary to facilitate an IPO.
4 Bioxel filed for a Canadian offering of units consisting of one common share and one-half of a common share purchase warrant.